GAVI Alliance has announced that Pfizer’s pneumococcal conjugate vaccine, Prevenar 13 (pneumococcal polysaccharide conjugate vaccine [13-valent, adsorbed]), is now included in the expanded pediatric immunization program in Tanzania. Pneumococcal disease is one of the leading causes of vaccine-preventable deaths worldwide in children younger than 5 years of age and results in more than one out of every five deaths in children younger than 5 years of age in Tanzania.
The availability of Prevenar 13 in Tanzania is made possible by the Advance Market Commitment (AMC), a funding mechanism that provides newer vaccines on a sustainable, affordable, and accelerated basis to the world’s poorest countries. In just two years, 20 countries, including Tanzania, have introduced Prevenar 13 into their immunization programs as part of the AMC. This potentially lifesaving vaccine is being offered to help protect an estimated 10.5 million infants and children in these developing countries from pneumococcal pneumonia and invasive disease caused by the serotypes in the vaccine.
While public health interventions have helped to decrease infant mortality in Tanzania by 47 percent between 1990 and 2010, mortality rates are still among the highest in the world. There are more than 100,000 deaths of Tanzanian children under the age of 5 every year.
Pfizer will supply up to 480 million doses of Prevenar 13 under the AMC to help expand immunization programs against pneumococcal disease by 2023.
Release Date: December 5, 2012
Source: The Associated Press